Shots:

• The P-IIa POC study involves assessing GSK3640254 (GSK’254- qd) in 34 treatment-naïve adults with HIV. The study is divided into 2 parts- in part 1- patients received GSK’254 (10/200mg) vs PBO for 10days and in part 2- patients got GSK’254 (40/80140 mg) vs PBO for 7days
• The study showed the antiviral activity b/w dose and antiviral response with 140 & 200mg doses demonstrating the reduction in plasma HIV-1 RNA. The largest mean changes in viral load were -1.5 log10 & -2.0 log10 copies/ml with these doses respectively
• These findings support its P-IIb study that evaluates GSK’254 as part of combination therapy for treatment naïve adults living with HIV

 ­ Ref: ViiV Healthcare | Image: ViiV Healthcare